John Maraganore
Insider (Form 4 reporting owner): Director CIK 1180432Name as filed: MARAGANORE JOHNIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 19 Jan 2016, sold $80.5M in 17 sales and bought $249K in 1 open-market purchase across 3 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | Chief Executive Officer | 19 Jan 2016 | 12 Nov 2021 | – | 16$78.5M |
| Agios Pharmaceuticals AGIO | Director | 11 Sep 2018 | 12 Sep 2018 | – | 1$2.0M |
| Rapport Therapeutics RAPP | Director | 22 Oct 2026 | 22 Oct 2026 | 1$249K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | no trade old enough | no trade old enough | no trade old enough |
| After sales | -17.6 pts16 trades, 0.00% above the sector | -29.6 pts16 trades, 0.00% above the sector | +9.4 pts16 trades, 94% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | 1 | $249K | – | – | $249K |
| 2021 | – | – | 4 | $22.1M | -$22.1M |
| 2020 | – | – | 4 | $18.6M | -$18.6M |
| 2019 | – | – | 2 | $7.4M | -$7.4M |
| 2018 | – | – | 2 | $7.3M | -$7.3M |
| 2017 | – | – | 2 | $19.0M | -$19.0M |
| 2016 | – | – | 3 | $6.1M | -$6.1M |
Every trade
19, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 22 Oct 2026 | Rapport Therapeutics RAPP | Buy | 9,411 | $26.45 | $249K | No | Form 4filed 22 Oct 2026 |
| 12 Nov 2021 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 33,978 | $171.52 | $5.8M | Not stated | Form 4filed 12 Nov 2021 |
| 13 Aug 2021 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 33,979 | $199.78 | $6.8M | Not stated | Form 4filed 16 Aug 2021 |
| 13 May 2021 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 33,979 | $130.78 | $4.4M | Not stated | Form 4filed 17 May 2021 |
| 25 Feb 2021 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 33,979 | $147.31 | $5.0M | Not stated | Form 4filed 26 Feb 2021 |
| 19 Nov 2020 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 34,765 | $124.23 | $4.3M | Not stated | Form 4filed 20 Nov 2020 |
| 20 Aug 2020 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 34,765 | $136.13 | $4.7M | Not stated | Form 4filed 21 Aug 2020 |
| 20 May 2020 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 34,765 | $143.22 | $5.0M | Not stated | Form 4filed 22 May 2020 |
| 20 Feb 2020 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 34,765 | $131.85 | $4.6M | Not stated | Form 4filed 21 Feb 2020 |
| 14 Oct 2019 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 49,456 | $79.45 | $3.9M | Not stated | Form 4filed 16 Oct 2019 |
| 15 May 2019 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 49,457 | $70.00 | $3.5M | Not stated | Form 4filed 17 May 2019 |
| 12 Sep 2018 | Agios Pharmaceuticals AGIO | Sellamended filing (4/A), not counted again | 0 | Not filed | Not filed | Not stated | Form 4/Afiled 6 Nov 2018 |
| 11 Sep 2018 | Agios Pharmaceuticals AGIO | Sell | 27,717 | $72.23 | $2.0M | Not stated | Form 4filed 13 Sep 2018 |
| 25 Jul 2018 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 50,000 | $105.39 | $5.3M | Not stated | Form 4filed 27 Jul 2018 |
| 22 Nov 2017 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 73,415 | $130.90 | $9.6M | Not stated | Form 4filed 24 Nov 2017 |
| 15 Nov 2017 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 74,000 | $126.86 | $9.4M | Not stated | Form 4filed 17 Nov 2017 |
| 19 Jul 2016 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 30,151 | $64.70 | $2.0M | Not stated | Form 4filed 21 Jul 2016 |
| 19 Apr 2016 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 30,151 | $67.46 | $2.0M | Not stated | Form 4filed 21 Apr 2016 |
| 19 Jan 2016 | Alnylam Pharmaceuticals ALNY | Sellafter exercising options | 30,152 | $71.78 | $2.2M | Not stated | Form 4filed 21 Jan 2016 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.